Target(s)
- Sigma Pharmaceuticals (Australia) Pty Ltd
Summary
Aspen Pharmacare Holdings Limited proposed to acquire Sigma Pharmaceuticals (Australia) Pty Ltd and two other entities from Sigma Company Limited. Sigma Pharmaceuticals (Australia) includes Sigma's pharmaceutical products manufacturing, marketing and supply business including in respect of all prescription, generic and private label products.Statement of issues
Public competition assessment
Undertakings
Timeline
| Date | Event |
|---|---|
| 06/09/2010 | ACCC commenced review under the Merger Review Process Guidelines. |
| 27/09/2010 | Closing date for submissions from interested parties. |
| 08/10/2010 | ACCC requested further information from the merger parties. ACCC timeline suspended. |
| 20/10/2010 | ACCC received further information from the merger parties. ACCC timeline recommenced. |
| 27/10/2010 | ACCC published a Statement of Issues outlining preliminary competition concerns. |
| 11/11/2010 | Closing date for submissions relating to Statement of Issues. |
| 12/11/2010 | ACCC received further information from the merger parties. Former proposed date for announcement of ACCC's findings of 25 November 2010 amended to allow for consideration of the information provided. |
| 30/11/2010 | Draft 87B undertaking proffered by Aspen. ACCC commenced market inquiries on the draft undertaking. |
| 07/12/2010 | Closing date for submissions relating to draft 87B undertaking. |
| 16/12/2010 | ACCC announced it would not oppose the proposed acquisition, subject to court enforceable undertaking offered by Aspen Pharmacare Holdings Limited and Aspen Asia Pacific Pty Ltd, and in light of Aspen deciding to excise Sigma's iron polymaltose product, Ferrosig, from the acquisition. |
| 16/12/2010 | 87B undertaking accepted by ACCC. |